Curasight
9 following
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Read moreShowingAll content types
Dagens aktienyheder 10/12: Spar Nord, Embla Medical, Curasight
Curasight A/S announces outcome of warrant exercise
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Curasight: SEB maintain valuation range midpoint at DKK 54 per share
Curasight: The last day of trading in warrants of series TO2 is on the 3[rd] of December 2024
Dagens aktienyheder 26/11: Asetek og Curasight
Curasight: Interview med CEO Ulrich Krasilnikoff og CSO Andreas Kjær efter aflagt 3. kvartalsregnskab
BioStock: Curasight CEO reflects on a Q3 with strong progress
Curasight – Opdatering på 3. kvartal 2024
Dagens aktienyheder 25/11: Curasight
Curasight and Curium sign global radioisotope supply agreement for uTREAT[®]
Dagens aktienyheder 21/11: Scandinavian Medical Solutions og Curasight
Curasight: Q3 report and exercise period in warrant TO2 starts
Curasight: The exercise period for warrants of series TO2 commences today
Curasight: Interim report Q3 2024
Dagens aktienyheder 20/11: Vestjysk Bank, Penneo A/S, Scandinavian Medical Solutions og Curasight
Curasight: The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share
Dagens aktienyheder 18/11: SP Group, Gabriel, Pharma Equity Group, Curasight og Scandinavian Medical Solutions
Wrap-Up from the Deep Dive on Brain Cancer (GBM)
